Recent Updates
Recently added Catalysts
HUMA Positive Sentiment Score: 80/100

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

Friday, November 24, 2023 2 min read
Key Takeaway: Humacyte, Inc. (Nasdaq: HUMA) announced that its leadership will present at the Piper Sandler 35th Annual Healthcare Conference in New York on November 30, 2023. CEO Laura Niklason and CFO Dale Sander will participate in a fireside chat and are available for one-on-one meetings. The company specializes in developing universally implantable bioengineered human tissues, with its initial portfolio targeting several vascular applications currently in late-stage clinical trials.

Market Sentiment Analysis

POSITIVE FACTORS

  • Humacyte is developing innovative bioengineered human tissues.
  • The company received important FDA designations for its products.
  • Presentation at a prestigious healthcare conference indicates strong interest and visibility.

Full Press Release Details

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Piper Sandler 35th Annual Healthcare Conference, in New York, NY on November 30, 2023. Management will also be available for one-on-one meetings.
Event: Piper Sandler 35th Annual Healthcare Conference
Location: The Lotte New York Palace, New York, NY
Fireside Chat: Thursday, November 30, 8:00-8:25 a.m. ET
Webcast: Access the live presentation here.
A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Humacyte website.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
LifeSci Advisors LLC
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Precision Strategies
rich@precisionstrategies.com

Frequently Asked Questions

When is Humacyte presenting at the Piper Sandler conference?

Humacyte will present on November 30, 2023.

Where does the Piper Sandler conference take place?

The event is at The Lotte New York Palace, New York, NY.

What is Humacyte's main focus in biotechnology?

Humacyte develops universally implantable bioengineered human tissues.

What is the status of Humacyte's HAV for hemodialysis?

Humacyte’s 6mm HAV is in late-stage clinical trials with FDA designations.

Who are the key speakers at the conference?

Laura Niklason and Dale Sander will be presenting.

Tags: HUMA Viatris Investor Conferences Healthcare Humacyte biotechnology Piper Sandler bioengineered tissues
Last updated: Nov 24, 2023